Anti -Lipoprotein Receptor-related Protein 5, Low Density (LRP5, BMND1, HBM, HGNC:6697, LR3, LRP7, Osteoporosis Pseudoglioma Syndrome, OPPG, OPS, VBCH2)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 2; NC_000002.11 (169983619..170219123, complement). Location: 2q31.1

Polyclonal

IgG

Sheep

Recognizes human LRP-5.

Affinity Purified
Purified by immunoaffinity chromatography.

Supplied as a lyophilized powder in PBS, trehalose. Reconstitute with sterile PBS to 200ug/ml.

Lyophilized powder may be stored at -20 degree C. Stable for 12 months at -20 degree C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Reconstituted product is stable for 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Small volumes of anti-LRP2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

LRP-5 (low-density lipoprotein receptor-related protein 5) is a 1615aa, 180-200kD type I transmembrane glycoprotein. The 1353aa extracellular domain (ECD) contains 20 class B LDLR, 4 EGF-like, and 3 class A LDLR repeats. Human LRP-5aa 745-1097 encompasses class B LDLR repeats #12-17 and EGF-like repeat #3. It shares 94aa identity with mouse and rat LRP-5, and 70aa identity with human LRP-6 within corresponding regions. LRP-5 and LRP-6 mediate DKK effects on Wnt signaling. LRP-5 polymorphisms correlate with susceptibility and resistance to osteoporosis.

Antibodies; Abs to Disease Markers

Western Blot (WB)

Suitable for use in Western Blot.
Dilution: Western Blot: 1ug/ml

521,958 Da[Similar Products]

low density lipoprotein receptor-related protein 2

low-density lipoprotein receptor-related protein 2; LRP-2; megalin; glycoprotein 330; calcium sensor protein; Heymann nephritis antigen homolog

Low-density lipoprotein receptor-related protein 2

LRP-2; gp330??[Similar Products]

LRP2_HUMAN

The protein encoded by this gene, low density lipoprotein-related protein 2 (LRP2) or megalin, is a multi-ligand endocytic receptor that is expressed in many different tissues but primarily in absorptive epithilial tissues such as the kidney. This glycoprotein has a large amino-terminal extracellular domain, a single transmembrane domain, and a short carboxy-terminal cytoplasmic tail. The extracellular ligand-binding-domains bind diverse macromolecules including albumin, apolipoproteins B and E, and lipoprotein lipase. The LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, vitamin-binding proteins, and hormones. This protein also has a role in cell-signaling; extracellular ligands include parathyroid horomones and the morphogen sonic hedgehog while cytosolic ligands include MAP kinase scaffold proteins and JNK interacting proteins. Recycling of this membrane receptor is regulated by phosphorylation of its cytoplasmic domain. Mutations in this gene cause Donnai-Barrow syndrome (DBS) and facio-oculoacoustico-renal syndrome (FOAR).[provided by RefSeq, Aug 2009]

LRP2: Acts together with cubilin to mediate HDL endocytosis. May participate in regulation of parathyroid- hormone and para-thyroid-hormone-related protein release. Defects in LRP2 are the cause of Donnai-Barrow syndrome (DBS); also known as faciooculoacousticorenal syndrome (FOAR syndrome). DBS is a rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g. agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. Belongs to the LDLR family.

Protein type: Receptor, misc.; Membrane protein, integral; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 2q31.1

Cellular Component: Golgi apparatus; endoplasmic reticulum; endocytic vesicle; lysosome; brush border membrane; lysosomal membrane; apical plasma membrane; plasma membrane; integral to membrane; coated pit; endosome; receptor complex

Molecular Function: protein binding; calcium ion binding; SH3 domain binding

Biological Process: steroid metabolic process; cell proliferation; receptor-mediated endocytosis; phototransduction, visible light; forebrain development; protein amino acid glycosylation; endocytosis; lipid metabolic process; retinoid metabolic process; vitamin D metabolic process

Disease: Donnai-barrow Syndrome

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.